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The majority of genes in the human genome consists of multiple exons interspersed with introns that undergo splicing to form mature mRNA and protein products 1, 2 . Although alternative splicing (AS) provides cells with a means to diversify the proteome (Fig. 1a) , recent studies have revealed multiple ways by which splicing is pathologically altered to promote the initiation and/or maintenance of cancer. These include mutations in regulatory sequences of critical cancer-associated genes that affect splicing 3, 4 , as well as mutations [5] [6] [7] [8] [9] [10] [11] [12] and gene expression alterations [13] [14] [15] that affect core and/or accessory components of the spliceosome complex (Fig. 1b) . Consistent with this, systematic transcriptomic analyses across cancer types have revealed widespread alterations in alternative, as well as constitutive, splicing (Box 1) relative to those in their normal tissue counterparts 3, 4, [16] [17] [18] . These findings highlight the possibility that manipulation of splicing might provide therapeutic benefit in cancer. Splicing requires multiple proteinprotein and protein-RNA interactions and is directed by a number of trans-acting proteins, which themselves are subjected to regulation by post-translational modifications and protein-RNA interactions for normal function. This multitude of interactions and regulatory steps provides a wide array of means to manipulate the splicing cascade for therapeutic purposes. In this Review, we highlight the current and developing strategies to target aberrant splicing events, as well as enhanced dependency, on the spliceosome in cancer.
The spliceosome and splicing regulation Splicing is carried out by the spliceosome, a large (mega-dalton) complex of RNA and proteins consisting of five small nuclear ribonucleoprotein particles (snRNPs: U1, U2, U4, U5 and U6) and more than 200 proteins. Several recent studies have elucidated the structures of numerous components of the spliceosome at unprecedented, near-angstrom resolution [19] [20] [21] [22] . Basic mechanisms for normal RNA splicing (reviewed in detail recently [23] [24] [25] [26] ) require cis-regulatory elements and trans-acting factors that bind to these elements to promote splicing and/or recruitment of the spliceosome. Each of these elements may be subjected to various forms of dysregulation during the course of tumorigenesis (Fig. 1b) . The key cis elements necessary for splicing are the 5′ and 3′ splice sites, which are located at intron-exon junctions, and the branch-point region near the 3′ splice site, where the U2 snRNP binds to mark the formation of the pre-spliceosome. Additional sequences within exons (exonic splicing enhancers (ESEs) and exonic splicing silencers (ESSs)) and introns (intronic splicing enhancers (ISEs) and intronic splicing silencers (ISSs)) are critical for correct exon recognition and modulation of splicing outcome. These additional regulatory sequences are recognized by proteins that regulate splicing, which may be differentially expressed in tissues to regulate tissue-specific splicing patterns. The majority of these auxiliary splicing-regulating proteins belong to the serine-and arginine-rich (SR) 27 protein and heterogeneous nuclear ribonucleoprotein (hnRNP) 28 families, but numerous additional proteins that do not belong to these two families have also been shown to promote or repress splicing.
Splicing alterations in cancer
Systematic genomic analyses of the transcriptional characteristics of cancer, as well as the coding and noncoding mutations present across cancers, have repeatedly identified alterations that affect splicing in diverse cancer types. Prior to the public deposition of high-depth mRNA sequencing (RNA-seq) data from a wide variety of cancer types, analysis of cancer transcriptomes using expressed-sequence-tag (EST) libraries suggested that cancer cells have 'noisier' splicing than their normal tissue counterparts, with a higher number of transcripts containing premature termination codons (PTCs), consistent with an increased rate of mis-splicing relative to that in normal tissues 17 .
Analysis of this data by dividing genes into oncogenes versus tumor suppressor genes, using data from more than 30 different human cancer types, revealed a far greater frequency of PTCs in transcripts encoded by tumor suppressor genes than in those encoded by oncogenes, suggesting that this process is non-random 17 .
Mutations in splice-site sequences. Recent RNA-seq analyses of tumor and paired normal tissues from the same individuals have further elucidated global, cancer-associated splicing features. Analysis of RNAseq data across 16 distinct cancer types from The Cancer Genome Atlas (TCGA) revealed that common RNA processing differences exist between cancer cells and their normal tissue counterparts 18 . Notably, almost all of the cancer types analyzed had abnormalities in intron retention that affected both constitutive and alternatively spliced introns, which occurred far more commonly than alterations in other types of splicing events, including cassette exon splicing, or 5′ or 3′ splice site recognition (Fig. 1a) . Although an overriding molecular explanation for aberrant intron retention across cancers was not evident from this work, several specific molecular alterations have been associated with increased intron retention among cancer types. For example, in clear-cell renal cell carcinoma, increased intron retention has been associated with loss-of-function mutations in SETD2, which encodes a histone H3 Lys36 (H3K36) methyltransferase, resulting in the loss of H3K36 trimethylation at target exons 29 .
Two recent studies integrating data from whole-exome, wholegenome and RNA-seq analyses from the same patients have provided further insights into the effects of somatic mutations in cancer on RNA splicing 3, 4 . These analyses provided robust evidence that somatic singlenucleotide variants (SNVs) affecting splicing were associated with intron retention more commonly than cassette exon splicing or other categories of AS in an allele-specific manner. Moreover, SNV-induced intron retention was substantially more enriched in tumor suppressor genes than in oncogenes, potentially owing to the fact that almost all of the intron-retention events resulted in the generation of PTCs, whereas only ~50% of cassette exon splicing events would result in generation of a PTC 4 . Of note, SNVs affecting the splice sites of TP53 (which encodes p53), ARID1A (which encodes a chromatin-remodeling factor that is frequently mutated in cancer) and PTEN (which encodes a phosphatase that regulates phosphatidylinositol 3-kinase (PI3K) signaling) were among the most commonly affected tumor suppressor genes in this study 4 . This is consistent with several well-described and clinically important mutations that function to activate proto-oncogenes by altering their splicing, including mutations causing exon 14 skipping in the proto-oncogene MET (which encodes a receptor tyrosine kinase involved in growth factor signaling) in lung cancer [30] [31] [32] (Fig. 1c) and those activating a cryptic splice site in NOTCH1 (which encodes a trans-membrane receptor involved in various developmental processes) that results in an aberrantly active form of NOTCH1 in chronic (refs. 30,113) . On the right is shown an alternative splicing event affecting expression of CD19. Mutations affecting exon 2 of CD19 result in a stable form of CD19 lacking the segment encoded by exon 2 (CD19 exon2∆ ), which is not recognized by T cells expressing CD19-specific chimeric antigen receptors 42 . Moreover, SRSF3 promotes inclusion of exon 2, and downregulation of SRSF3 expression has similarly been suggested to result in expression of CD19 exon2∆ .
npg r e v i e w 9 7 8 VOLUME 22 | NUMBER 9 | SEPTEMBER 2016 nature medicine lymphocytic leukemia 33 . It is of note that in studies of cancer-associated mutations, although mutations at intronic splicing donor or acceptor sites are commonly recognized to be deleterious, a substantial proportion of somatic mutations affecting splicing may occur as synonymous mutations within exons that affect ESE or ESS sequences 3 (Fig. 1b) . Although synonymous exonic mutations might alter gene function in a variety of ways other than by affecting splicing, one study suggests that synonymous exonic mutations are enriched within oncogenes versus those in tumor suppressor genes and that they tend to cluster within 30 nt of an exon boundary 3 . Such cancer-associated synonymous mutations that are close to exon boundaries seem to preferentially result in a gain of ESE motifs and a loss of ESS motifs, a situation not frequently seen with synonymous mutations in tumor suppressor genes 3 .
Mutations in genes encoding splicing factors. In parallel to the work described above, numerous studies have now highlighted that RNA splicing factors themselves are recurrently affected by somatic mutations, which occur predominantly in hematological malignancies and, to a lesser extent, in epithelial cancers (Fig. 1a) . The known mechanistic consequences of these mutations have been reviewed recently 34, 35 , and it seems that these mutations, which mainly affect the genes encoding the splicing factors SF3B1 (refs. [36] [37] [38] [39] [40] . Moreover, these mutations occur exclusively as heterozygous point mutations at restricted residues and, in diseases in which mutations in each of these genes are common, in a
Box 1 Glossary
A complex. A complex of the spliceosome assembled on an intron of a pre-mRNA, in which U2 snRNP is recruited to the branch-point sequence (BPS) through interactions with the U2AF complex. U2 snRNP binds the BPS to complete formation of the A complex in a step that requires ATP.
Alternative splicing (AS). A highly regulated process in which different mRNA isoforms can be produced from the same gene by altering the exonic and/or intronic sequences included in the mature mRNA.
Branch-point sequence (BPS). A short conserved intronic sequence located near the 3′ end of the intron that is recognized by the U2 snRNP complex during pre-spliceosome formation. This is further stabilized by U2 auxiliary factors (U2AFs) to mark the 3′ position of the splicing reaction. The branch point is then covalently linked to the 5′ splice site to form an intronic lariat that is later removed by the spliceosome.
Cassette exon splicing. A splicing event in which an intervening exon between two other exons may be included or excluded from the mature mRNA sequence to yield two distinct alternative isoforms. Cassette exon splicing events constitute the most common form of alternative splicing.
Constitutive splicing. A splicing event in which the order of the exons in the mature mRNA is invariably the same as the arrangement in the pre-mRNA.
Cryptic splice site. A splice site that is not normally used in a canonical splicing reaction but that is aberrantly activated in a diseased or pathological condition. It can be caused by mutations in the underlying DNA sequence or by de-regulation of RNA splicing factors.
Cis-regulatory elements-splicing enhancers and silencers (ESE, ESS, ISE and ISS)
. Short DNA motifs located within exonic or intronic regions of pre-mRNAs that regulate the recruitment of trans-acting factors that promote (such as SR proteins) or repress (such as hnRNPs) splicing. The combinations of these regulatory proteins dictate the eventual splicing outcome. These cis elements can be categorized into exonic splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs) and intronic splicing silencers (ISSs).
E complex. The earliest complex of the spliceosome assembled on an intron of pre-mRNA. It is formed through an ATP-independent reaction in which U1 snRNP binds the 5′ splice site, SF1 binds the branch-point sequence, and U2AF binds the polypyrimidine tract.
Expressed-sequence-tag (EST) libraries. A public database containing short fragments of complementary DNA (cDNA) sequences cloned from a cDNA library and used to identify a transcript of a given transcribed gene. Currently there are over 74 million eukaryotic ESTs available from over 1,000 species.
Heterogeneous nuclear ribonucleoproteins (hnRNPs).
A family of RNA-binding proteins that have various roles in RNA metabolism, including RNA splicing. Several hnRNPs regulate pre-mRNA splicing in trans and generally suppress splicing.
Intron retention. A splicing event in which an intron is retained in the mature mRNA transcript instead of being removed during splicing.
Nuclear speckles. Structures that are enriched for a complex of RNA and pre-mRNA splicing factors and that are located in inter-chromatin regions in the nucleoplasm. The protein and RNA-protein components of speckles can dynamically move in and out of the speckles depending on the transcriptional state of the cell.
Premature termination codon (PTC).
A codon located at an inappropriate location 5′ to the normal termination codon in transcribed mRNA that does not translate into an amino acid and hence signals the end of translation prior to the normal termination codon.
Small nuclear ribonucleoproteins (snRNPs). RNA-protein complexes composed of small ribonuclear RNAs (snRNAs) and several different Sm ribonucleoproteins that are normally found in the nucleus and involved in RNA splicing. The major spliceosome complex is made up of different snRNPs (U1, U2, U4, U5 and U6), which assemble at defined locations on pre-mRNA in a precise and coordinated manner to complete the splicing reaction.
Serine-and arginine-rich proteins (SR proteins). A family of RNA-binding proteins, each member of which contains an RNA-recognition motif (RRM) and an arginine- and serine-rich (RS) domain for protein-protein interactions. SR proteins generally promote splicing and may also have roles in mRNA export, nonsense-mediated decay and translation.
npg mutually exclusive manner with one another 5 . The mutual exclusivity of mutations in genes encoding splicing factors, along with their consistent heterozygous state, suggests a requirement for wild-type splicing function in the presence of a mutant splicing factor, a possibility that requires formal evaluation. In addition to mutations that alter RNA splicing by changing the function of trans-acting splicing factors or altering the splice sites of cancer-associated genes in cis, a series of studies has also identified numerous examples in which altered expression of splicing-regulating proteins, even in the absence of mutation, promotes oncogenesis (reviewed recently 41 and Fig. 1b) . In addition, a recent study found a case in which alteration in the expression of a splicing regulatory protein affected response to cancer therapy. In this study, it was found that an alteration in SRSF3 expression in B cell acute lymphoblastic leukemia (B-ALL) cells influences splicing of CD19 (which encodes a cell surface receptor on B cells), resulting in impaired recognition of these cells by CD19-specific chimeric antigen receptor (CAR) T cells, which would normally target the cells for degradation 42 (Fig. 1c) . Studying the mechanistic details by which alterations in splicing proteins contribute to cancer pathogenesis and/or resistance to treatment will therefore be important, given the potential methodologies to therapeutically modify these events and/or their downstream consequences (Fig. 2) . Moreover, a deeper understanding of the splicing alterations involved in disease pathogenesis and resistance to treatment may be instrumental in guiding clinical decisions regarding the use of therapies that target splicing, which are described below.
Methods to target splicing in cancer
Modulation of the core spliceosome to therapeutically target cancer. Over the last two decades, multiple bacterially derived products and their analogs have been shown to bind the SF3B component of the U2 snRNP to disrupt the early stages of spliceosome assembly. These compounds-which include FR901463, FR901464 and FR901465 (from Pseudomonas sp. 2663) 43, 44 and unrelated, structurally distinct compounds derived from Streptomyces (herboxidienes (from Streptomyces sp. A7847) 45 and pladienolides (from Streptomyces platensis Mer-11107) 46 ,47 ) ( Table 1 )-were originally identified as being potently cytotoxic and resulting in cell cycle arrest in the G1 and G2/M phases of the cell cycle (reviewed previously 48, 49 ). Although these earliest natural compounds showed promising anticancer properties in various in vitro and in vivo studies, with half-maximal inhibitory concentrations (IC 50 values) in the low nanomolar ranges, they were chemically unstable and thus unsuitable for therapeutic purposes. Total synthesis [50] [51] [52] [53] [54] and further efforts to identify analogs of herboxidienes and pladienolides resulted in the successful development of additional compounds with improved stability, most notably E7107 (ref. 55) (an analog of pladienolide B), spliceostatin A (SSA; from FR901464) 56 and the sudemycins 57 (Table 1) .
Eleven years after the initial description of these compounds, two studies using different target identification approaches showed that SSA (a methylated derivative of FR901464) and E7107 bind noncovalently to the SF3B component of U2 snRNP and impair pre-mRNA splicing in a dose-and time-dependent manner 55, 56 . These effects were mimicked by RNA interference (RNAi)-mediated silencing of SF3B1 (ref. 56 ) and later were confirmed by splice-sensitive microarrays 58 . In addition, both studies identified that although exposure to these drugs resulted in nuclear accumulation of the majority of unspliced pre-mRNAs, a minor fraction of unspliced pre-mRNAs leaked out of the nucleus and was able to generate stable, aberrant protein products 55, 56 (Figs. 2 and 3) . Notably, treatments with SSA 56 , E7107 (ref. 55) or GEX1A 59 (a form of herboxidiene) resulted in the production of an aberrantly truncated form of the cell cycle inhibitor )). In addition, identification of proteins stably produced by aberrant splicing in cancer may result in therapeutic strategies to target these downstream pathologic products and pathways (e). Additional therapeutic strategies that have been shown to affect splicing in only cell-free in vitro assays are not shown. Perturbation of U2 snRNP by modulation of SF3B1 function or methylation of Sm proteins is shown in more detail in Figure 3 . The location of U1 snRNP and U2 snRNP binding, as well as some of the components important in recruitment of U2 snRNP to the 3′ splice site (U2AF1, U2AF2 and ZRSR2) are shown.
npg r e v i e w 9 8 0 VOLUME 22 | NUMBER 9 | SEPTEMBER 2016 nature medicine p27 (encoded by CDKN1B), which retains its normal function but is unusually stable due to truncation of the C-terminal domain necessary for its normal proteolytic degradation. Despite the convergent effects of FR901464 and the structurally distinct pladienolides, the exact component of the SF3B complex targeted by these compounds was not fully resolved. SF3B is a 450-kDa complex comprised of seven subunits: SF3B1, SF3B2, SF3B3, SF3B4, SF3B5, SF3B14 and PHF5A (Fig. 3) . Initially, SF3B1 was identified to be the most enriched protein that bound to SSA 56 , whereas SF3B3 was initially suggested to be the main target of E7107 (ref. 55) . Of note, a functional genetic study performed several years later clarified that SF3B1 is the target of both classes of compounds 60 , data which has confirmed that all of the cellular effects of these compounds can be attributed to SF3B1 binding. These findings were based on the characterization of two separate human colorectal cancer cell lines that acquired resistance to pladienolide B following long-term exposure to the compound. RNAseq analysis of both resistant and parental cells revealed that resistant cells acquired a point mutation in SF3B1 (SF3B1 R1074H ) 60 . Subsequent functional validation confirmed that this specific mutation confers resistance by reducing the binding affinity of each compound to SF3B1, abolishing the inhibitory effects on pre-mRNA splicing. This same point mutant of SF3B1 also confers resistance to the sudemycins, providing further evidence that SF3B1 is the definitive target of these two major classes of spliceosome-modulatory compounds 60 . These data suggest that, despite being structurally distinct, SSA, the pladienolides and the herboxidienes seem to interact with SF3B1 in exactly the same manner. Although it is clear that these compounds influence pre-mRNA splicing by binding to SF3B1 and destabilizing the interaction of U2 snRNP with pre-mRNA (Fig. 3) , the proposed mechanistic effects of these compounds on splicing differ across studies. In early spliceosome assembly, U2 snRNP is recruited to the branch point within the 3′ end of the intron, via interaction between SF3B1 and the splicing factor U2AF65. ATP-dependent stabilization of the interaction between U2 snRNP and the branchpoint sequence (BPS) is a hallmark of pre-spliceosome assembly 23, 24, 26 . In one study, it was proposed that E7107 exposure results Cpd-1 inhibits SRPK1, SRPK2, CLK1, and CLK2.
Cpd-3 inhibits CLK1 and CLK2 much more than SRPK1 and SRPK2.
• Results in widespread splicing alterations with accelerated degradation of aberrantly spliced mRNAs
• Suppresses SR protein phosphorylation, and causes dissociation of nuclear speckles
Preclinical studies limited to in vitro studies in MDA-MB-468 breast cancer cells 92 .
Compounds described to modulate splicing only in non-mammalian cells 106 or purely based on cell-free assays, and/or with indirect effects on splicing 107-109 , are not described in this in defective spliceosome formation at the step in which U2 snRNA binds pre-mRNA, by inhibiting the exposure and binding of the branch-point-binding region (BBR) of U2 snRNA to the BPS, an important conformational change in U2 snRNP that ensures binding fidelity to pre-mRNA that is essential for the transition from the E to the A complex in the splicing cascade 61 . In contrast, another study using SSA suggested that SSA interferes with splicing after U2 snRNP has stably integrated at the transition of the pre-spliceosome to the B complex 62 . However, more recent work has revealed that the mechanistic effects of these three main classes of SF3B1-targeting compounds are likely to be similar. Each of these compounds was able to inhibit cell-free in vitro splicing at 1 µM, whereas addition of the inactive analogs of each compound restored splicing 63 . Moreover, the inactive analogs of each of these compounds can interfere with the function of the active versions of each compound in an interchangeable fashion, suggesting a shared mechanism of splicing modulation among these compounds 63 . Despite the mechanistic insights regarding the interaction of SF3B1-targeting compounds with U2 snRNP, greater systematic efforts to characterize the effects of these compounds on the transcriptome are needed. Our recent work revealed that in vivo treatment with E7107 resulted in changes to all classes of AS events, including retained introns, cassette exons, and competing 5′ and 3′ splice sites 64 . At the same time, most alternative and constitutive splicing events were unchanged by E7107 treatment, and prior work has demonstrated that the strength of the 3′ splice site is an important determinant for which splice sites are affected by SF3B1-binding compounds 58 . Further efforts to understand the splicing changes mediated by these compounds may be important in predicting the effects of these compounds in disease. Similarly, a more systematic effort to identify the effects of splicing-inhibitory compounds on the proteome is needed. It is entirely possible that the cellular effects of these compounds can be attributed to the generation of aberrant protein products, beyond p27, which themselves might be toxic to cells.
Preclinical and clinical evaluation of splicing modulation in cancer.
The recent discovery of mutations in genes encoding splicing factors in cancer has prompted interest to understand whether cancer cells with mutations in such genes might have preferential sensitivity to compounds that interrupt splicing. Recent work 64, 65 has revealed that the presence of a wild-type splicing factor is required for survival of cells that express a mutant splicing factor. Moreover, in vivo E7107 treatment of isogenic murine myeloid leukemias with or without mutant Srsf2 revealed preferential cell death of leukemia cells bearing mutated Srsf2 (ref. 64) . Similar synthetic-lethal interactions between expression of mutated U2AF1 and exposure to sudemycins have also been reported 66 . Further genomic analysis in isogenic cancer cells with or without mutations in splicing-factor-encoding genes will be important in identifying whether there are specific pre-mRNA sequence features that can predict responsiveness to these compounds and/or whether specific mis-spliced targets can be identified that are responsible for the preferential lethality in the context of splicingfactor-mutant cells.
There has also been an interest in understanding whether targeting splicing might have therapeutic use in cancers that are driven by specific pathologic splicing events. For example, nearly 30% of human melanomas with a Val600Glu mutation in the BRAF proto-oncogene (BRAF V600E ) develop BRAF inhibitor resistance by expressing a splice variant of BRAF V600E that lacks the RAS-binding domain (RBD) 67 . Recent work has identified that at least one human melanoma cell line developed acquired resistance to the BRAF inhibitor vemurafenib, owing to an intronic mutation in BRAF that resulted in an in-frame skipping of exons 3-5, which encode the RBD. Notably, use of SSA or a related analog meayamycin B 52 ( Table 1) restores inclusion of the exons encoding the RBD and can overcome splicing-mediated vemurafenib resistance both in vitro and in vivo 68 . Although this study elegantly demonstrated the utility of reversing diseaseassociated aberrant splicing events, it also highlighted the potential for more focused modulation of specific pathologic splicing events in cancer (described below).
In parallel to biochemical studies, preclinical studies and medicinal chemistry efforts, clinical trials assessing the therapeutic potential Figure 3 Pharmacologic methods to disrupt core spliceosome function. Current methods that directly inhibit spliceosome function include a series of compounds (including the pladienolides, herboxidienes and spliceostatins) that bind to the SF3B1 component of U2 snRNP and inhibit early spliceosome assembly 55, 56 . These are represented in the blue boxes. Perturbation of U2 snRNP function has been shown to result in widespread intron retention and cassette exon skipping in a time- and dose-dependent manner in a variety of cell types 58, 64 . While this results in an accumulation of pre-mRNAs in the nucleus, pharmacologic perturbation of U2 snRNP is also associated with leakage of pre-mRNA into the cytoplasm 55, 56 . Although most unspliced mRNAs are expected to become substrates for nonsense-mediated decay (NMD), a portion of these mRNAs may undergo translation to generate aberrant protein products that may have cellular toxicity. In addition to SF3B1-targeting compounds, recent data suggests that inhibition of Sm protein methylation via downregulation of PRMT5 may also inhibit splicing 74, 105 . The seven Sm proteins of U2 snRNP (shown in purple) include SmB and SmB′ (encoded by alternatively spliced transcripts), SmD1, SmD2, SmD3, SmE, SmF and SmG. PRMT5 symmetrically methylates arginine residues of SmB or SmB′, SmD1 and SmD3. 69 . At the same time, although the drug was generally well tolerated and a maximal tolerated dose was established, an unexpected toxicity of bilateral optic neuritis was identified in three patients and resulted in suspension of both trials 69, 70 . Currently it is unclear whether this toxicity, which was not encountered in preclinical animal studies 64, 71 , is an on-target effect of SF3B1 inhibition or a toxicity effect specifically associated with E7107. Future clinical trial efforts will be needed to understand the safety and potential therapeutic efficacy of other structurally distinct forms of the pharmacologic modulators of SF3B1 that have been described.
Potential for spliceosome modulation in MYC-oncogene-dependent cancers.
Although mutations in splicing-factor-encoding genes have highlighted the potential for cancers bearing these alterations to be targeted by general spliceosome modulation, numerous reports have suggested that MYC-dependent cancers may also be preferentially vulnerable to spliceosome modulation. First, a number of splicingregulating proteins that promote transformation are direct transcriptional targets of MYC. This includes MYC-induced upregulation of hnRNPA1 and hnRNPA2, which in turn, regulate alternative splicing of the cancer-associated muscle pyruvate kinase (PKM) isoform 72 .
In addition, SRSF1 is also directly upregulated by MYC, and SRSF1 drives transformation of mammary epithelial cells in collaboration with MYC 73 . A recent study showed that in MYC-driven B cell lymphomas, MYC directly upregulates the transcription of several genes encoding core snRNP factors, as well as genes encoding factors involved in snRNP assembly, including Prmt5, which encodes an arginine methyltransferase that methylates the Sm proteins of U2 snRNP 74 (Fig. 3) . Prmt5 knockdown in MYC-driven lymphomas resulted in exon skipping and intron retention, as well as in the abrogation of lymphoma development in mice 74 , suggesting that cells overexpressing MYC rely on high levels of PRMT5 and mature snRNPs to sustain splicing fidelity. This is a therapeutically exciting possibility, given the recent development of pharmacologic inhibitors of PRMT5 (ref. 75) . At the same time, it should be noted that PRMT5 has substrates other than splicing-related proteins, which are probably critical for cellular function (reviewed recently 76, 77 ). Moreover, several other mechanisms, unrelated to RNA processing or splicing, in which cancer cells are sensitized to PRMT5 inhibition have recently been proposed 78, 79 . Further efforts to understand the effects of pharmacologic inhibition of PRMT5 on splicing, its therapeutic index and its roles in MYC-dependent cancers will be critical. Another related study using RNAi screens identified a unique vulnerability of MYC-expressing glioblastoma cells and mammary epithelial cells to downregulation of splicing factors as compared to cells transformed by other oncogenes, such as RAS, EGFR or HER2. First, an effort to identify genes required for growth and viability of patient-derived glioblastoma stem cells (GSCs) revealed a preferential requirement for PHD finger protein 5A (PHF5A) 80 in the survival of GSCs versus that in untransformed neural stem cells. PHF5A encodes a protein required to facilitate the interaction between U2 snRNP and ATP-dependent helicases 81 . Accordingly, pharmacologic perturbation of U2 snRNP with SSA or sudemycin C revealed potent therapeutic efficacy in GSCs. Efforts to understand the molecular alterations that might underlie responsiveness to PHF5A depletion or to disruption of U2 snRNP led the authors to identify that expression of MYC in neural stem cells induced sensitivity to U2 snRNP perturbation 80 .
A more recent study aimed at identifying essential genes in the context of MYC-overexpressing mammary epithelial cells revealed that several splicing factors are required to tolerate MYC hyperactivation. This includes BUD31, whose function has not previously been elucidated in mammalian cells 82 . This study showed that BUD31 associates with multiple subcomplexes of the spliceosome and that BUD31 depletion is associated with global intron retention, suggesting a role for BUD31 in normal splicing function. These findings then led the authors to perform a series of experiments whose results suggested that MYC dependency (as indicated by sensitivity to MYC downregulation by RNAi) correlates with dependency on spliceosomal proteins (as indicated by RNAi-mediated downregulation of spliceosomal components) 82 . Moreover, pharmacologic perturbation of SF3B1 with sudemycin D in vivo increased survival and limited metastasis in xenograft models for breast cancer, suggesting a clear potential for therapeutic translation of these findings.
Although these data suggest an enhanced dependency for spliceosomal protein expression in MYC-driven cancers, the therapeutic index of this approach and specificity for MYC-driven cancers versus other genetic subsets of cancer need to be clarified further. Each of the above studies reports distinct mechanisms by which MYC-expressing cells become preferentially dependent on spliceosome function that seem to be lineage specific 74, 80, 82 . Whereas this may be related to the known context-dependent regulation of splicing 23 , further understanding of the mechanisms by which MYC affects splicing may be important for future therapeutic efforts to target MYCdependent cancers.
Targeting splicing-regulating proteins in cancer. In addition to modulating splicing by modulation of the core spliceosome, the identification that splicing-regulating proteins promote oncogenesis after overexpression [13] [14] [15] 83 , as well as by alteration-of-function 37, 39, 40, 84 mutations (Fig. 1) , have highlighted the potential for therapeutic targeting of these proteins as novel cancer therapies. In particular, inhibition of phosphorylation of SR proteins has emerged as a potential means to modulate splicing by altering the function of splicingregulating proteins. SR proteins belong to a family of proteins that is required for constitutive splicing, as well as for modulating alternative splicing. They are highly conserved in eukaryotes and have one or two RNA-recognition motifs (RRMs) at the amino terminus and an arginine-and serine-rich (RS) domain at the C terminus (reviewed recenty 27, 28 ). The RS domains consist of multiple consecutive RS-SR dipeptide repeats that undergo extensive phosphorylation by multiple kinases, including members of the SR protein kinase (SRPK) family (SRPK1 and SRPK2), hPRP4, topoisomerase I and the CDC2-like kinase (CLK) family (CLK1 to CLK4) (reviewed recently 85, 86 ) . Although the precise physiological function of SR protein phosphorylation is not well defined, experimental induction of either hyper-or hypophosphorylation of SR proteins inhibits splicing 87 . For example, expression of kinase-dead mutant forms of the SRPK or CLK proteins results in global inhibition of splicing and enlargement of nuclear speckles 88, 89 . Table 1) . Although the genome-wide effects of TG-003 are not well characterized, the drug seems to affect expression of the functional isoforms of SRSF2 and CLK1, alterations that may themselves be therapeutically important targets 90 .
A recent large-scale screen for compounds that inhibit SRPK kinase activity uncovered a series of three compounds (Cpd-1, Cpd-2 and Cpd-3; Table 1 ) that seem to inhibit SPRK1, SRPK2 and/or CLK1 and CLK2 (ref. 91) . Comparison of the inhibitory effects of the Cpd compounds against the SPRK proteins, the CLK proteins and 28 other kinases suggests some specificity of these compounds for the SRPK and/or CLK kinases, but larger efforts to understand their kinase specificity will be important 92 . In addition, direct comparison of the effects on splicing of SF3B1-targeting compounds versus compounds affecting SR protein phosphorylation may help elucidate distinct effects of these two therapeutic approaches. In addition, further preclinical studies are needed to understand the potential therapeutic relevance of SR protein inhibitors for cancer therapy and whether any genetic or histologic subtypes of cancer are more susceptible to these compounds.
Oligonucleotide therapy to modulate splicing in cancer. Given the widespread alterations of splicing that are expected to result from global spliceosome perturbation and the increased identification of specific pathologic splicing events important in cancer, there has been continued interest in targeting individual splicing events with oligonucleotide-based therapeutics. Such oligonucleotides can be designed to hybridize to RNA in a sequence-specific manner through Watson-Crick base-pairing to alter splicing. The advantages of oligonucleotide-based therapies to modulate splicing include the vast myriad ways they can potentially modify splicing, as described below. At the same time, it is important to note that despite dozens of years of effort, no form of oligonucleotide-based therapy has been approved by the US Food and Drug Administration (FDA) for the treatment of cancer (the use of oligonucleotides to modulate gene expression through induction of RNA cleavage or suppression of translation will not be discussed here but has been reviewed recently 91, 93, 94 ). Nonetheless, oligonucleotide-based therapies seem extremely promising for the correction of specific pathologic splicing events underlying non-cancer-related monogenic disorders. Indeed, such therapies are currently in late-stage clinical trials for patients affected by Duchenne muscular dystrophy (DMD) 95 and spinal muscular atrophy (SMA) 96 , providing continued motivation to explore the modulation of splicing as a potential cancer therapy.
As of now, oligonucleotides have been identified that modulate splicing for the repair of defective mRNA, restore the production of essential proteins, generate novel proteins and regulate the presence of disease-related splice variants. So-called splice-switching oligonucleotides (SSOs) have most commonly been used to manipulate splicing by preventing the interaction of splicing molecules with pre-mRNA through steric hindrance, without inducing cleavage of the RNAs. For example, some exons are poorly included in mRNA because they contain ESS sequences or are adjacent to ISS sequences, which recruit splicing inhibitory factors to prevent inclusion of the exons in the pre-mRNA. Binding of SSOs to such sites to block recruitment of splicing inhibitory factors would be expected to promote exon inclusion. In fact, the oligonucleotide therapy that is most advanced in clinical trials for SMA blocks an ISS element to promote exon inclusion in a manner which restores effective expression of the protein which is pathologically reduced and causative of SMA 97 . Conversely, efforts to manipulate splicing through binding of SSOs to ESEs or ISEs have also been demonstrated to promote exon exclusion. In fact, the use of SSOs to promote skipping of exons containing disease-causative frame-shift or nonsense mutations constitutes the therapeutic strategy that has been used clinically in DMD 95 . Exon skipping mediated by SSOs in this manner is associated with slower disease progression in mice, as it promotes expression of an internally deleted, partially functional version of the protein that is pathologically reduced in DMD 98, 99 .
Although the success and safety of SSOs in treating neuromuscular disorders is promising, the therapeutic effect of modulating splicing of a single event within cancer cells is unclear, especially given the widespread alterations in splicing that have been described in most common forms of cancer. However, the discovery of alteration-offunction mutations and overexpression of splicing factors in cancer highlights the potential use of SSOs to target the function of wild-type and/or mutant splicing factors themselves. For instance, recent studies have highlighted that mutations in SRSF2 alter SRSF2's RNA binding and splicing preference in a sequence-specific manner 37, 84 and that expression of mutant SRSF2 is sufficient to drive a clonal hematopoietic disorder 37 . This opens up the possibility that SSOs targeting the ESE preferred by the mutant SRSF2 protein may have therapeutic impact in SRSF2-mutated malignancies. At the same time, recent work has also identified that the wild-type SRSF2 protein is essential for the survival of cells expressing mutated SRSF2 (ref. 64 ), owing to the observation that cells expressing mutant SRSF2 alone have substantially altered gene expression and splicing that are incompatible with cell survival. This suggests that SSOs targeting the ESE recognized primarily by wild-type SRSF2 might be an alternative therapeutic approach for targeting SRSF2-mutant cells. Similarly, the identification of ESE motifs that are recognized by SRSF1 (refs. 100,101) provides a potential ability to target SRSF1 binding in cancer types thought to be driven by SRSF1 overexpression. It is of note, however, that the sequences recognized by SR proteins, hnRNP and other splicing-regulating proteins may not provide much specificity, and this could result in similar widespread alterations in splicing as those seen with SF3B1 or SR kinase inhibitors. Thus, further efforts to understand and prioritize the pathologic splicing events driven by altered splicing factors in cancer are greatly needed. For example, several recent studies have identified that SF3B1 mutations result in the widespread use of cryptic 3′ splice sites and suggest that this is basis for its pathologic effects in cancer 39, 40 . In fact, altered splicing of mRNAs encoding specific iron-transport proteins (such as ABCB7 (ref. 39 ) and mitoferrin-1 (ref. 102)) has been suggested to mediate the hematopoietic disorder most closely linked to SF3B1 mutations, termed refractory anemia with ring sideroblasts (RARS), a subtype of the myelodysplastic syndromes. Thus, use of SSOs to correct splicing of these specific events within SF3B1-mutated leukemias may be a novel and targeted therapeutic approach to correct mutationassociated splicing events driving the disease phenotype.
Conclusion
A number of diverse mechanisms by which splicing is dysregulated in cancer have been described and have highlighted the need to understand and identify means to therapeutically manipulate splicing in potential cancer therapies. Although a number of chemical npg compounds that modulate splicing catalysis have been described to date, nearly all of these drugs inhibit early spliceosome assembly or SR protein phosphorylation; however, it is quite likely that additional chemical screens will identify compounds that modulate the spliceosome at later stages of splicing catalysis than the currently described compounds targeting SF3B1. It is also possible that the increased structural understanding of the spliceosome, as has been achieved recently [20] [21] [22] , will help to elucidate the mechanistic effects of these compounds and suggest novel means of splicing perturbation.
In parallel to identifying new therapeutic modalities that target splicing, further clarification of the therapeutic index for existing methods of general spliceosome targeting and of the genetic subsets of cancer most susceptible to the effects of these compounds is needed. Numerous preclinical models have suggested, somewhat unexpectedly, that modulating the activity of the spliceosome in general is well tolerated in vivo. These studies have also suggested a potential rationale for the use of these compounds in cancers that are driven by MYC.
At this point, clinical evaluation of compounds other than E7107 will be necessary to definitively address the safety, potential therapeutic effects and toxicity effects of splicing modulation in patients. In addition to MYC-driven cancers, several studies have now suggested that cancer cells bearing mutations in splicing-factor-encoding genes are actually dependent on the presence of the wild-type splicingfactor-encoding allele 64, 65 , providing a rationale for therapeutically targeting wild-type splicing function in these cancers. Given the altered splicing preferences generated by these mutations, the use of oligonucleotides to manipulate splicing may be a very attractive idea for cells that have spliceosomal gene mutations. Further biological studies to prioritize and functionally characterize the altered splicing events that link mutant splicing factors to the cancer phenotype may be very important for future targeted therapeutic approaches. For instance, it is possible that novel, aberrant proteins generated in the context of splicing-factor-encoding gene mutations may render these cells susceptible to pharmacological and immunological agents that target the encoded proteins or their associated pathways. Moreover, the widespread alterations in splicing that result from targeting SF3B1 and SR protein phosphorylation may themselves generate aberrant proteins that could be used for immunological targeting of cancer cells. Further efforts to understand the effects of these compounds on the proteome could identify aberrant proteins that are recurrently generated in the presence of these drugs and may also be important in this regard. Thus, an increased understanding of splicing in cancer is highly likely to advance our understanding of cancer pathogenesis, in addition to nominating a broad array of novel therapeutic approaches.
